A new strategy reported engineered CAR Tregs to counter birch pollen allergy by directing cell therapies against soluble allergens. The approach focuses on controlling immune inflammation through regulatory T cells rather than conventional effector cell killing. The preclinical findings suggest an avenue for antigen-specific control of allergic disease caused by pollen, food allergens, or dust mites—where conventional treatments often manage symptoms rather than targeting the allergic trigger. For developers, the key technical implication is immune modulation at the antigen level, potentially enabling more durable disease control while reducing broader immunosuppression concerns.